Literature DB >> 33552376

Cochrane corner: universal screening for SARS-CoV-2 infection.

Duduzile Ndwandwe1, Lindi Mathebula1,2, Olatunji Adetokunboh3,4, Raoul Kamadjeu5, Charles Shey Wiysonge1,4,6.   

Abstract

INTRODUCTION: coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most people infected with SARS-CoV-2 have mild disease with non-specific symptoms, although a few becoming critically ill with septic shock and multiple organ failure. There is an unknown proportion of infected individuals who remain asymptomatic and infectious. Universal screening for COVID-19 infections to detect individuals who are infected before they present clinically could therefore be an important measure to contain the spread of the disease. We highlight a Cochrane rapid review which assessed the effectiveness and accuracy of universal screening for COVID-19 infection.
METHODS: the authors of the Cochrane review searched multiple electronic databases to identify studies reporting on the effectiveness of universal screening and reporting on screening test accuracy. Eligible participants for the review included people who had not sought care for potential COVID-19 symptoms.
RESULTS: the authors included 22 publications, with none of them conducted in Africa. Two modelling studies reported on the beneficial and negative effects of screening; and 20 studies (cohort and modelling) reported data on the accuracy of screening tests. The included studies had wide variability in the baseline prevalence of COVID-19 infection as well as study settings and methods. All cohort studies compared screening strategies to reverse transcriptase-polymerase chain reaction (RT-PCR) as the gold standard. The rapid review suggests that there is low certainty of evidence that screening at travel hubs may slow the importation of infected cases. Furthermore, the review highlights the uncertainty and variation in the accuracy of screening.
CONCLUSION: given the low accuracy of the tests included in this review, a high proportion of COVID-19 infected individuals may be missed and go on to infect others. In addition, some healthy individuals may be falsely identified as positive, requiring confirmatory testing and potentially leading to the unnecessary isolation of these individuals. Copyright: Duduzile Ndwandwe et al.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; Universal screening; screening test accuracy

Mesh:

Year:  2020        PMID: 33552376      PMCID: PMC7846260          DOI: 10.11604/pamj.supp.2020.37.48.26881

Source DB:  PubMed          Journal:  Pan Afr Med J


  10 in total

1.  Exit and Entry Screening Practices for Infectious Diseases among Travelers at Points of Entry: Looking for Evidence on Public Health Impact.

Authors:  Varvara A Mouchtouri; Eleni P Christoforidou; Maria An der Heiden; Cinthia Menel Lemos; Margherita Fanos; Ute Rexroth; Ulrike Grote; Evelien Belfroid; Corien Swaan; Christos Hadjichristodoulou
Journal:  Int J Environ Res Public Health       Date:  2019-11-21       Impact factor: 3.390

2.  Universal screening for SARS-CoV-2 before labor admission during Covid-19 pandemic in Madrid.

Authors:  Ignacio Herraiz; Dolores Folgueira; Cecilia Villalaín; Laura Forcén; Rafael Delgado; Alberto Galindo
Journal:  J Perinat Med       Date:  2020-11-26       Impact factor: 1.901

3.  Universal screening for novel coronavirus disease 2019 (COVID-19) for asymptomatic parturients: May not be beneficial at this time.

Authors:  Cassandra E Henderson; Shadi Rezai; Janelle M Jackman
Journal:  J Med Virol       Date:  2020-09-28       Impact factor: 2.327

4.  Entry screening to delay local transmission of 2009 pandemic influenza A (H1N1).

Authors:  Benjamin J Cowling; Lincoln L H Lau; Peng Wu; Helen W C Wong; Vicky J Fang; Steven Riley; Hiroshi Nishiura
Journal:  BMC Infect Dis       Date:  2010-03-30       Impact factor: 3.090

5.  Universal screening for SARS-CoV-2 infection: a rapid review.

Authors:  Meera Viswanathan; Leila Kahwati; Beate Jahn; Kayla Giger; Andreea Iulia Dobrescu; Christine Hill; Irma Klerings; Jana Meixner; Emma Persad; Birgit Teufer; Gerald Gartlehner
Journal:  Cochrane Database Syst Rev       Date:  2020-09-15

6.  The prospects for the SARS-CoV-2 pandemic in Africa.

Authors:  Virginia Quaresima; Matteo M Naldini; Daniela M Cirillo
Journal:  EMBO Mol Med       Date:  2020-05-05       Impact factor: 12.137

7.  COVID 19: Should we consider universal screening in trauma patients?

Authors:  Nirmal Raj Gopinathan; Siddhartha Sharma; Karthick S Rangasamy; Mandeep S Dhillon
Journal:  Injury       Date:  2020-06-15       Impact factor: 2.586

8.  Universal screening for the SARS-CoV-2 virus on hospital admission in an area with low COVID-19 prevalence.

Authors:  Sangeeta R Sastry; Rachel Pryor; Jillian E Raybould; Julie Reznicek; Kaila Cooper; Amie Patrick; Shelley Knowlson; Pamela Bailey; Emily Godbout; Michelle Doll; Michael P Stevens; Gonzalo Bearman
Journal:  Infect Control Hosp Epidemiol       Date:  2020-07-23       Impact factor: 3.254

9.  Detection of imported COVID-19 cases worldwide: early assessment of airport entry screening, 24 January until 17 February 2020.

Authors:  Varvara A Mouchtouri; Zacharoula Bogogiannidou; Martin Dirksen-Fischer; Sotirios Tsiodras; Christos Hadjichristodoulou
Journal:  Trop Med Health       Date:  2020-09-14

10.  Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV).

Authors:  Billy J Quilty; Sam Clifford; Stefan Flasche; Rosalind M Eggo
Journal:  Euro Surveill       Date:  2020-02
  10 in total
  3 in total

1.  Performance and usefulness of a novel automated immunoassay HISCL SARS-CoV-2 Antigen assay kit for the diagnosis of COVID-19.

Authors:  Kaori Saito; Tomohiko Ai; Akinori Kawai; Jun Matsui; Yoshiyuki Fukushima; Norihiro Kikukawa; Takuya Kyoutou; Masayoshi Chonan; Takeaki Kawakami; Yoshie Hosaka; Shigeki Misawa; Haruhi Takagi; Yasushi Matsushita; Makoto Hiki; Atsushi Okuzawa; Satoshi Hori; Toshio Naito; Takashi Miida; Kazuhisa Takahashi; Yoko Tabe
Journal:  Sci Rep       Date:  2021-12-01       Impact factor: 4.379

2.  Impact of Mass Workplace COVID-19 Rapid Testing on Health and Healthcare Resource Savings.

Authors:  Francesc López Seguí; Jose Maria Navarrete Duran; Albert Tuldrà; Maria Sarquella; Boris Revollo; Josep Maria Llibre; Jordi Ara Del Rey; Oriol Estrada Cuxart; Roger Paredes Deirós; Guillem Hernández Guillamet; Bonaventura Clotet Sala; Josep Vidal Alaball; Patricia Such Faro
Journal:  Int J Environ Res Public Health       Date:  2021-07-03       Impact factor: 3.390

3.  A Cost-Benefit Analysis of the COVID-19 Asymptomatic Mass Testing Strategy in the North Metropolitan Area of Barcelona.

Authors:  Francesc López Seguí; Oriol Estrada Cuxart; Oriol Mitjà I Villar; Guillem Hernández Guillamet; Núria Prat Gil; Josep Maria Bonet; Mar Isnard Blanchar; Nemesio Moreno Millan; Ignacio Blanco; Marc Vilar Capella; Martí Català Sabaté; Anna Aran Solé; Josep Maria Argimon Pallàs; Bonaventura Clotet; Jordi Ara Del Rey
Journal:  Int J Environ Res Public Health       Date:  2021-06-30       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.